?
Home
About
Company Overview
History
Group Structure
ESG
Management Team
R&D
Technology Platform
505(b)(2) NDA
High Barrier ANDA
Corporate
Board of Directors
Committee
Internal Audit
Major Internal Policies
Investor
Company Profile
Financials
Shareholders’ Services
Stakeholder
News
Contact
Location
Join Us
Home
About
Company Overview
History
Group Structure
ESG
Management Team
R&D
Technology Platform
505(b)(2) NDA
High Barrier ANDA
Corporate
Board of Directors
Committee
Internal Audit
Major Internal Policies
Investor
Company Profile
Financials
Shareholders’ Services
Stakeholder
News
Contact
Location
Join Us
訊息中心
News
媒體報導
Material Information- Announcement of the Execution Results of the Company’s Treasury Share Buyback
2026-11-06
Material Information- Announcement of the record date for the issuance of restricted employee shares
2026-11-05
Material Information- Announcement of the Board’s Resolution to redeem and cancel restricted employee shares for a capital reduction
2026-11-05
Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers
2026-11-05
Material Information- Announcement on behalf of the subsidiary, Handa Pharma, Inc, regarding the change in over one-third of directors
2026-11-05
Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q3.
2026-11-05
Material Information- Announces Handa Pharmaceuticals, Inc., and on behalf of the subsidiaries, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit
2026-11-04
Material Information-The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities
2026-11-04
Material Information- The Company was invited to attend the in-person meeting hosted by IBF Securities
2026-09-29
Material Information- The Company was invited to attend the in-person meeting hosted by KGI Securities
2026-09-15
1
2
3
…
6
›